|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Research and development expenses | |||||
| Operating loss | |||||
| Impairment of investment | |||||
| Impairment loss on PPE | |||||
| Other income, net | |||||
| Loss before income taxes | |||||
| Income tax expense/benefit | |||||
| Net loss attributable to common stockholders | |||||
| Foreign currency translation adjustments | |||||
| Comprehensive loss | |||||
| Net loss per share attributable to common stockholders: | |||||
| Basic and diluted (in Dollars per share) | |||||
| Weighted-average number of shares used in computing loss per share amounts: (in Shares) | |||||
Loading...
